Shree Ganesh Biotech (India) rose 4.01% to Rs 185.50 after the company's board recommended a 10-for-1 stock split.
The board of Shree Ganesh Biotech (India) in its meeting on 20 December 2021, recommended the proposal of splitting the company's shares from face value Rs 10 each to face value of Re 1 each.Shree Ganesh Biotech (India) reported net profit of Rs 0.82 crore in Q2 September 2021 as against net loss of Rs 0.04 crore in Q2 September 2020. Net sales were reported at Rs 17.96 crore in Q2 September 2021. No sales were reported in the same quarter last year.
Shree Ganesh Biotech (India) is engaged in the trading of seeds and bhushi. It is mainly into the business of production, processing and marketing of high quality hybrid seeds for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app